RECRUITING

Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to understand the role of GLP-1 in the pathogenesis of T2D in youth and explore their potential salutary effects and ability to delay the progressive loss of ß-cell function and reduce hepatic steatosis in youth with prediabetes/new onset T2D and NAFLD.

Official Title

Semaglutide, 2.4mg, Once Weekly: Effects on Beta-cell Preservation and Reduction of Intrahepatic Triglyceride Content in Obese Youth With Prediabetes (IGT)/Early Type 2 Diabetes (T2D) and Non-Alcoholic Fatty Liver Disease (NAFLD)

Quick Facts

Study Start:2023-07-17
Study Completion:2027-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05067621

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:10 Years to 21 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:CHILD, ADULT
Inclusion CriteriaExclusion Criteria
  1. Age 18 years or older
  2. Willing and able to provide informed consent
  3. Able to understand and follow study procedures
  4. Stable medical condition
  1. Pregnancy or breastfeeding
  2. Severe psychiatric disorders
  3. Active substance abuse
  4. Unstable medical conditions
  5. Inability to comply with study requirements

Contacts and Locations

Study Contact

Julie Holub
CONTACT
203-785-5692
julie.holub@yale.edu
Theresa Goddard
CONTACT
203-785-5692
theresa.goddard@yale.edu

Principal Investigator

Sonia Caprio, MD
PRINCIPAL_INVESTIGATOR
Yale University

Study Locations (Sites)

Pediatric Diabetes Center
New Haven, Connecticut, 06511
United States

Collaborators and Investigators

Sponsor: Yale University

  • Sonia Caprio, MD, PRINCIPAL_INVESTIGATOR, Yale University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-07-17
Study Completion Date2027-01

Study Record Updates

Study Start Date2023-07-17
Study Completion Date2027-01

Terms related to this study

Keywords Provided by Researchers

  • Prediabetes
  • NAFLD
  • Impaired Glucose Tolerance
  • Semaglutide

Additional Relevant MeSH Terms

  • Type 2 Diabetes Mellitus
  • Impaired Glucose Tolerance
  • Non-Alcoholic Fatty Liver Disease
  • Obesity, Childhood